In this study of Epstein-Barr virus (EBV) latency, the polymerase chain reaction was used in modified form for amplification and detection of viral mRNA sequences in peripheral blood lymphocytes from healthy seropositive adults. Six known promoters for latent gene expression and eight known gene products were identified in in vitro-immortalized lymphocytes and in the cell lines established spontaneously from seropositive adults. We examined whether mRNA expression in uncultured B cells from four seropositive adults was the same as that which occurred in spontaneously established EBV-positive B-cell lines from the same individuals. A minimum of 17 polymerase chain reaction targets was required to circumscribe the known latent mRNA structures. Expression of the C promoter for the EBNA genes was detected in B-cell RNA from three of the four subjects. Transcripts initiated from the alternative W promoter for EBNA expression were not detected. The spliced transcripts detected in the B cells contained only the C2-to-Wl alternative splice, which was nonproductive for EBNA4 gene expression. None of the other EBNA open reading frames were detected spliced onto the 3' ends of the C promoter-initiated RNAs. Spliced RNA from the TP gene was detected in all four subjects. Expression of the TP gene was restricted to TP1 promoter-initiated RNAs, as no TP2 promoterinitiated transcripts were detected. Expression of RNA from the LMP gene was not detected. The F promoter which is active in the restricted expression latency that occurs in Burkitt's lymphoma cells was not detected being expressed in peripheral blood B cells. This pattern of latent gene expression is unique to uncultured B cells, indicating that there are profound differences between viral lptent states in vitro and in situ and suggesting a central role for the TP gene in the latency of EBV.
In this study of Epstein-Barr virus (EBV) latency, the polymerase chain reaction was used in modified form for amplification and detection of viral mRNA sequences in peripheral blood lymphocytes from healthy seropositive adults. Six known promoters for latent gene expression and eight known gene products were identified in in vitro-immortalized lymphocytes and in the cell lines established spontaneously from seropositive adults. We examined whether mRNA expression in uncultured B cells from four seropositive adults was the same as that which occurred in spontaneously established EBV-positive B-cell lines from the same individuals. A minimum of 17 polymerase chain reaction targets was required to circumscribe the known latent mRNA structures. Expression of the C promoter for the EBNA genes was detected in B-cell RNA from three of the four subjects. Transcripts initiated from the alternative W promoter for EBNA expression were not detected. The spliced transcripts detected in the B cells contained only the C2-to-Wl alternative splice, which was nonproductive for EBNA4 gene expression. None of the other EBNA open reading frames were detected spliced onto the 3' ends of the C promoter-initiated RNAs. Spliced RNA from the TP gene was detected in all four subjects. Expression of the TP gene was restricted to TP1 promoter-initiated RNAs, as no TP2 promoterinitiated transcripts were detected. Expression of RNA from the LMP gene was not detected. The F promoter which is active in the restricted expression latency that occurs in Burkitt's lymphoma cells was Epstein-Barr virus (EBV) is a ubiquitous lymphotropic human herpesvirus that is the causative agent of infectious mononucleosis and is associated with African Burkitt's lymphoma (BL) and undifferentiated nasopharyngeal carcinoma (12, 15, 19, 22) . The virus infects the host through the oropharynx, where it is capable of infecting epithelial cells and completing all of the steps of virus multiplication (29) . From this initial site, the virus also infects and replicates in infiltrating B lymphocytes (19) . Upon resolution of the primary infection, the virus persists in the host for life, being periodically detectable in throat washings and recoverable from the peripheral blood of seropositive adults as spontaneous immortalized B lymphocytes harboring latent virus (8, 16, 40) . EBV can also infect B cells in vitro and convert them into immortal lymphoblastoid cell lines (LCLs) (11) .
Two lines of evidence suggest that the cells in which the virus remains latent are resting B lymphocytes. (i) During prolonged acyclovir treatment, virus shedding in the oropharynx ceases; however, the frequency of establishment of spontaneously immortalized B-cell lines remains unchanged (39) . (ii) Analyses of EBV strains recovered from bone marrow transplant recipients strongly suggest that EBV can be eradicated from seropositive recipients during replacement of their hematopoietic cell lineages with bone marrow from seronegative donors (9, 14) . A still unanswered question about these latently infected B cells in circulation is how they are able to escape cell death induced by antigenspecific cytotoxic T cells. Such T-cell populations obtained from immunocompetent individuals readily kill autologous EBV-carrying LCLs in vitro (20, 21) . * Corresponding author.
These in vitro-maintained, latently infected cells express six nuclear antigens (EBNA1, EBNA2, EBNA3A, EBNA3B, EBNA3C, and EBNA4) and two membrane proteins (LMP and TP) (13) . Some of these gene products (EBNA2, EBNA3B, and LMP) have been shown to contain epitopes for cytotoxic T cells, and therefore it seems unlikely that the LCL-like cells could survive in situ (14) . EBV-carrying BL cells face the same challenge but are able to survive in the host by invoking a latent state in which viral gene expression is restricted to EBNA1 and host histocompatibility and adhesion molecules are reduced in number on the cell surface (10, 12, 18, 25, 33) . The surface characteristics of an immune resistant BL cell are very similar to those of a resting B cell.
It is not clear how the restricted latent viral gene expression is achieved, but studies on LCLs and BLs in vitro have shown that the controls include promoter switching, alternative splicing, and poly(A) site selection (26, 32, 34) . Classically, all of the EBNA genes are in a single 100-kbp transcription unit originating from one or the other of two promoters. The TATA-like element of the C promoter (so called because it lies within the BamHI C fragment) is located 26 bases upstream of the most complete cDNA and is directed toward IR1, the major internal repeat, just 304 bp away (3, 4) . The TATAAA element of the W promoter lies within the 3.1-kb repeating unit (the BamHI W fragment), 2.3 kb into the first repeat, and is reiterated in every successive repeat throughout the IR1 region (23, 28, 32, 35, 36) . There is some evidence that C and W promoters act in a mutually exclusive manner in LCLs and that during the initial stages of infection, use of the W promoter precedes use of the C promoter (37, 38 KCl . In addition, the oligonucleotides were designed to be free of potential secondary structure, self-complementarity, and complementarity with the other amplification primer oligonucleotides. The OLIGO primer design software (National Biosciences) was used to assist in locating sequences which fulfilled these criteria.
Expression of the six EBNA proteins is controlled by promoter switching, alternative poly(A) site selection, and alternative splicing (32). In Fig. 1 be polycistronic and also express the EBNA4 protein (31, 35) . The E3 primer lies within the short 5' exon which encodes the amino-terminal end of EBNA3C. This exon has been spliced into the leader of at least one EBNA1 message ( Fig. 1, JYK2 ) and therefore may not be solely representative of EBNA3C messages (i.e., T4, TE820, and IB4-T27).
To detect promoter usage and EBNA4 gene expression, we used a set of four sense primers which distinguish between C and W promoter-initiated transcripts and between alternative EBNA4-productive and nonproductive splices (see below The subjects used in this study were evaluated for anti-EBV antibody status to determine the titer of antibody against VCAs, EAs, and EBNA antigens. We used Western immunoblotting for this purpose because it is the most sensitive assay for EBV antibodies and provides information on the nature of the proteins involved in provoking the antibody response. All of our donors displayed a typical pattern of reactivity against a panel of antigen sources (Fig.  3) . All of the donors had antibodies against EBNA1, and three had antibodies against EBNA2 which were specific for the type A virus strain (type A viruses were present in the spontaneous LCLs established from these individuals). The sera also contained antibodies to viral proteins which are expressed late in the replication cycle and are components of the virion (unpublished data). were completely specific when the primers were tested against inappropriate cDNA targets (Fig. 4A) .
These four 5' primers were tested on total RNAs extracted from EBV-positive LCLs B95-8 (a C promoter-utilizing line) and X50-7 (a W promoter-utilizing line). The RNA was reverse transcribed by using the 3' common W2W1 splice junction oligonucleotide primer. The cDNA representing 104 cells was then aliquoted into PCR reactions with the four 5' primers and cycled through 25 amplifications. The products were electrophoresed on 2% agarose, blotted, and probed with a W1W2 splice junction probe (Fig. 4B) . Two observations were made. (i) The cell lines did appear to be exclusive in the use of C (B95-8) or W promoters (X50-7). Even at the PCR level of sensitivity, no leakiness of the nonfunctional promoter was observed. (ii) In both cell lines, the two alternative splices seemed to be made with approximately equal frequencies. This latter observation was difficult to confirm by the rudimentary quantitative PCR analyses we performed, but the conclusion is supported by Si primer extension analyses on unamplified RNA (23). We made reconstructions by using B95-8 or X50-7 cells diluted into a background of MOLT-4 cells and with 10 additional cycles of amplification were able to detect viral RNA from fewer than 10 cells, a range we suspected would be sufficient to detect EBV messages in PBLs.
For these studies, we used spontaneous LCLs isolated from healthy seropositive adults as controls for PCR amplification. The total RNA preparation for each of four spontaneous LCLs was amplified with the four primers for C and W as described above for B95-8 and X50-7 (Fig. 4C) . All of the cell lines were C start users, as anticipated from previous studies, and made both C2W1 and C2W1' splices. In addition, all of the LCLs used the W promoter but appeared to make more WOW1 splices than WOWl' splices. It is not clear why these LCLs display dual promoter usage, but it may have to do with the spontaneous lytic activation state, which is very high in LCLs of adult PBL origin. All of these spontaneous LCLs produce early antigens and VCAs, as determined by Western immunoblotting with human antiserum and RNA PCR with immediate-early, early, and late gene targets (data not shown). This observation was fortunate, because it allowed us to establish that all four 5' primers work on the in situ latent viruses from these individuals.
PBLs were collected from the four subjects and immediately processed by positive selection into B and non-B cells. The B cells were lysed, and total RNA was prepared. An aliquot representing approximately 5 x 106 cells was used in a cDNA reaction with the W2W1 splice junction oligonucleotide as the primer. This quantity of B cells might be expected to contain between 5 and 200 latent EBV-infected cells (16, 39, 40) . Our preliminary estimates using PCR and spontaneous-outgrowth assays suggest that the number is closer to 5 than to 200 (data not shown). We did not obtain ratios of infected to uninfected B cells that ever approached the 1:25,000 range that other investigators have reported for normal, healthy seropositive adults (40) .
The cDNA product was amplified through 35 cycles of PCR with each of the four 5' primers and analyzed by Southern hybridization with a W1W2 splice junction oligonucleotide probe (Fig. 4D) . The results revealed that the PBLs from three of the four donors had latently infected B cells which contained RNA initiated from the C promoter and processed only the C2W1 splice. RNA from one donor did not produce a detectable amplification product. This experiment was repeated twice with subsequent isolations of RNAs from these donors spanning a 6-month period. One of the positive donors scored negative on one occasion, and the consistently negative donor never gave a positive result for C promoter expression. Expression of EBNA1, EBNA2, EBNA3A, EBNA3B, and EBNA3C. The primers used for analysis of C and W promoter usage were designed to demonstrate that the spliced transcripts contained both Wl and W2 exons. In our experiences with PCR, and especially with RNA PCR, we have found that targets of fewer than 500 bases are the most efficient and therefore the easiest to detect from complex mixtures after amplification. When the PCR primers for the downstream ORFs were anchored at or near the 5' end of the transcript and contained a 'W1W2' repeating unit internally, the target size was greater than 1,000 bp and the yield from PCR reactions with LCL RNA targets was poor. In reconstruction experiments diluting LCL RNA into a background of EBV-negative RNA, these targets were found to be unsuitable for potential detection of expression from B-cell RNA preparations in which the number of expressing cells might be below 100 per reaction.
It was therefore necessary to use primers located in downstream leader exons as 5' anchors for the EBNA genes. For the EBNA2 and monocistronic EBNA4 messages, the 5' oligonucleotide anchor was placed within the W2 exon of the repeats. Although multiple initiation sites were present in long W1W2 repeat-containing cDNAs, successive rounds of amplification strongly favored short (<500 per bp) singlerepeat or lone W2-containing fragments. Reconstructions were performed in which B95-8 cells were diluted into a background of 106 MOLT-4 cells and RNA was extracted and subjected to 35 cycles of RNA PCR amplification (Fig.  5A ). These mock experiments showed that when the 5' W2 primer was used in combination with the 3' Y3P and Y3H1 primers, the products of both of these targets were detectable by Southern hybridization down to a dilution of 1 in 5 x 106 cells.
The tracks in Fig. 5B which contained the LCL RNA amplifications for the EBNA2 and EBNA4 targets contained multiple species. In the EBNA2 LCL amplifications, the band at 381 bp represents a cDNA with the structure W2-Y1-Y2-Y3P. The bands at 577 and 773 represent similar products which contained one or two additional W1-W2 repeats, respectively. The band at 513 bp has the structure W2-W2-Y1-Y2-Y3P, and the bands at 709 and 905 bp include additional W1-W2 repeats. These results come from probing of the Southern blots with probes for different exons and limited preliminary direct sequencing experiments on isolated bands. Use of the same techniques showed that the band at 256 bp in the EBNA4 LCL panel has a structure of W2-Yl-Y2-Y3-H1 and the band at 196 bp has the structure W2-Y1-Y2-H1. The bands at 452 and 392 bp, respectively, represent similar cDNA structures that contain additional W1-W2 repeat exons. None of the products characteristic of EBNA2 or EBNA4 monocistronic cDNA structures were detected in the B-cell RNA preparations (Fig. 5C) .
To screen for the presence of cDNA products representing expression of the downstream EBNA gene products (EBNA1, EBNA3A, EBNA3B, and EBNA3C), we used 3' primers located near the 5' end of the EBNA ORF and 5' primers located in W2, the F exon, and the Ul exon. The banding patterns of amplified cDNA products from LCLs using W2 and FQ as the 5' anchors were complex, largely as a result of alternative splicing, and are being investigated separately (data not shown). No comparable bands were detected in amplifications from B-cell RNA using these primers (data not shown). An important point, however, is that the principle bands detected in amplifications of LCLderived cDNAs of EBNA1, EBNA3A, EBNA3B, and EBNA3C messages all contained the Ul exon. A 5' primer located in Ul used in combination with the LI, E2, E3, or Ki 3' primer produced readily interpretable diagnostic banding on Southern blots. The 220-bp (Ul-Li), 287-bp (U1-E2), 253-bp (U1-E3), and 272-bp (Ul-Ki) bands represented splices from Ul to the ORFs for EBNA3A, EBNA3B, EBNA3C, and EBNA1, respectively. The structures of the additional bands that appeared in the Li-and Ki-primed amplifications were not determined. Reconstructions using LCLs diluted into a background of MOLT-4 cells produced detectable banding after 35 cycles of amplification down to 5 LCL cells per reaction for LI, E3, and Ki targets and 50 cells per reaction for the E2 target (Fig. SA) . By using hyperamplification with the same primers or nested primer sets, we were able to detect diagnostic bands from singlecell-containing reactions (data not shown). We were unable to detect U exon-EBNA ORF splice-containing transcripts in the RNA from PBLs (Fig. SC) . This strategy was promoter independent in the sense that products of any promoter, known or unknown, would have been detected so long as that promoter was located upstream of the U exon and the U exon was spliced into the final product. One possible reason for the failure to detect transcripts from the EBNA genes is that the DNA encoding these genes is not present in the B cells used to make the RNA. Although we used spontaneous LCLs derived from the peripheral blood of the same donors as the positive controls (Fig. 5) (Fig.  6 ). The EBNA2 target sequence from map positions 48419 to 48580 was 161 bp long and contained the 3' splice donor of the Y3 exon, the upstream untranslated region, the initiator methionine, and coding sequences for the first 26 amino acids of EBNA2. Similarly, the 161-bp band was detected in all LCLs and B cells (Fig. 6) Ti primer produced the diagnostic 168-bp band predicted from the published cDNA structure and a series of minor bands (Fig. 7) . The TP2 amplification target also yielded a doublet band of 173 bp (the predicted fragment) and 140 bp when LCL RNA was used in the PCR. (C) Donor B-cell RNA amplified with the same primer sets. Each blot was probed with a 32P-end-labeled oligonucleotide specific for a sequence near the 5' end of the target molecule. EBV-negative lymphocytes and then RNA extracted and PCR amplified showed that the TP1 target was detectable at the one-cell-per-reaction level while the TP2 target was detected at the five-cell-per-reaction level. All of the B-cell RNA preparations were positive for the 168-bp diagnostic TP1 fragment, and two also had the lower 140-bp fragment detected in some of the LCLs. The TP2 amplification target was not detected in the same B-cell RNA preparations (Fig.  7) .
The LMP gene product is expressed from a promoter operating in latently infected cells or from a separate promoter which is active in productive lytic viral replication (7, 27, 32) . We designed the LMP target for PCR to detect the latent type of transcript which includes two splices in a product of 480 bp (Fig. 2) . Reconstructions using the LMP primers and LCLs showed that the LMP target fragment of 480 bp was detectable at the five-cell-per-reaction level (Fig.  7A ). In the positive-control spontaneous LCLs, one cell line failed to score positive (Fig. 7B) (14) . These occur in immortalized cell lines maintained in vitro, BL cells, nasopharyngeal carcinoma cells, and other lymphoproliferative syndromes. The LCLs express the full range of six EBNA proteins, LMP, TP1, and TP2. The C promoter is most often used, and the productive EBNA4 splice is made in roughly half of the messages (23) . BL cells, and the group I phenotype cell lines established with them, express EBNA1 only and utilize a newly described latent promoter (F promoter) to accomplish this feat of restricted expression (28) . Nasopharyngeal carcinomas display similarly limited EBNA expression but also express the LMP gene, and the only cell line established from nasopharyngeal tumors also expresses TP2 RNA (5, 6, 30 Spliced transcripts from two of the latent promoters were detected. The products of the C promoter for the EBNA genes were detected in three of the four B-cell preparations from the subjects for whom spontaneous LCL controls were available. Including uncontrolled B-cell samplings from other individuals, C promoter activity was detectable in about 50% of the cases. Only the C2W1 nonproductive splice for EBNA4 gene expression was detected, indicating that a level of control over EBNA4 gene expression that has been suspected to occur appears to happen in peripheral blood B cells. Despite repeated attempts and hyperamplifications of RNA PCR reactions, it was not possible to detect the 3' structures of EBNA genes in the RNA samples that were positive for C promoter-initiated messages. These failures may mean that these structures do not occur in peripheral blood B cells and that a novel undefined 3' end exists. The only other latent promoter whose transcripts were detected was TP1. TP1 RNA was present in all of the B-cell RNA samples we examined, including uncontrolled samplings from six other individuals.
The state of latent viral gene expression in uncultured B cells thus appears to be unique. The TP1 gene seems to be always expressed, and the C promoter is often active. These findings are consistent with the hypothesis that a minimally active viral episome evades immune recognition of the cytotoxic T-cell epitopes on its EBNA2, EBNA3, and LMP proteins in a resting B cell. EBNA1 would not be necessary to maintain a viral genome in a nondividing cell. The function of TP1 in this latent scheme remains unclear; however, we have noted that it is a highly labile protein in LCLs (24) . TP1 has recently been found in plasma membrane-containing fractions of lymphoblastoid cells and may be associated with protein tyrosine kinases (17, 27) . A role for TP1 in reactivation of the latent virus in response to appropriate stimuli could be considered very possible.
One question that arises from these studies concerns the generation and maintenance in healthy adults of the antibody responses against the EBNA proteins and the EBV capsid components (Fig. 3) . We had anticipated that at least EBNA1 messages would be found since all our subjects and most, if not all, humans latently infected with EBV produce anti-EBNA1 antibodies. We did not find evidence of EBNA gene expression in latently infected cells. It therefore seems more likely that these responses are not made against latently infected B cells but rather might develop because of periodic reactivation of virus in latently infected cells (presumably not in circulation) and/or from the persistent challenge of new infections from the environment.
